{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:58:06Z","timestamp":1792619886145,"version":"4.5.0"},"reference-count":183,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Ionis Pharmaceuticals, Inc"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.cmet.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T11:39:21Z","timestamp":1522755561000},"page":"714-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":808,"title":["RNA-Targeted Therapeutics"],"prefix":"10.1016","volume":"27","author":[{"given":"Stanley T.","family":"Crooke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Frank","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda F.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2018.03.004_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.cmet.2018.03.004_bib2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.cmet.2018.03.004_bib3","series-title":"Methods and Compositions for Treating a SerpinC1-Associated Disorder. WO 2015\/175510","author":"Akinc","year":"2015"},{"key":"10.1016\/j.cmet.2018.03.004_bib4","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/jco.2012.30.15_suppl.3062","article-title":"Open-label extension study of the RNAi therapeutic ALN-VSP02 in cancer patients responding to therapy","volume":"30","author":"Alsina","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cmet.2018.03.004_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1042\/bst0240630","article-title":"Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors","volume":"24","author":"Altmann","year":"1996","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.cmet.2018.03.004_bib6","first-page":"4575","article-title":"A phase I open label, dose escalation trial of QPI-1007 delivered by a single intravitreal (IVT) injection to subjects with low visual acuity and acute non-arteritic anterior ischemic optic neuropathy (NAION)","volume":"54","author":"Antoszyk","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cmet.2018.03.004_bib7","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for syl1001, a novel short interfering rna for the treatment of dry eye disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cmet.2018.03.004_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cmet.2018.03.004_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cmet.2018.03.004_bib10","series-title":"Methods of Treating Transthyretin (ttr) Mediated Amyloidosis. WO\/2016\/033326","author":"Bettencourt","year":"2016"},{"key":"10.1016\/j.cmet.2018.03.004_bib11","first-page":"S282","article-title":"ISIS-GCCRRX, a novel glucocorticoid (GC) receptor antisense drug reduces cholesterol and triglycerides and attenuates dexamethasone induced hepatic insulin resistance without systemic GC antagonism in normal subjects","volume":"56","author":"Bhanot","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2018.03.004_bib12","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/bjc.2013.619","article-title":"First-in-human\u00a0Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer","volume":"109","author":"Bianchini","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cmet.2018.03.004_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.cmet.2018.03.004_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cell.2014.03.008","article-title":"The noncoding RNA revolution-trashing old rules to forge new ones","volume":"157","author":"Cech","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2018.03.004_bib16","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/jco.2011.29.15_suppl.3025","article-title":"Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement","volume":"29","author":"Cervantes","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cmet.2018.03.004_bib17","series-title":"Toxicology Data Network","article-title":"Patisiran","year":"2017"},{"key":"10.1016\/j.cmet.2018.03.004_bib18","series-title":"Toxicology Data Network","article-title":"Revusiran","year":"2017"},{"key":"10.1016\/j.cmet.2018.03.004_bib19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdw068","article-title":"A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers","volume":"27","author":"Chi","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cmet.2018.03.004_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.cmet.2018.03.004_bib21","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S0959-8049(16)33031-3","article-title":"A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)","volume":"69","author":"Chowdhury","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cmet.2018.03.004_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2018.03.004_bib23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib24","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","author":"Crooke","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib25","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"3","article-title":"Mechanisms of antisense drug action, an introduction","author":"Crooke","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib26","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated safety assessment of 2\u2032-O-Methoxyethyl Chimeric Antisense Oligonucleotides in nonhuman primates and healthy human volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The Effects of 2\u2032-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cmet.2018.03.004_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/nat.2017.0693","article-title":"The effects of 2\u2032-O-Methoxyethyl oligonucleotides on renal function in humans","volume":"28","author":"Crooke","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib30","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications","volume":"203","author":"D\u2019Souza","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.cmet.2018.03.004_bib32","series-title":"Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician\u2019s Approach","first-page":"117","article-title":"Spinal muscular atrophies","author":"Darras","year":"2014"},{"key":"10.1016\/j.cmet.2018.03.004_bib33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tig.2017.01.003","article-title":"Biogenesis and function of ago-associated RNAs","volume":"33","author":"Daugaard","year":"2017","journal-title":"Trends Genet."},{"key":"10.1016\/j.cmet.2018.03.004_bib34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","article-title":"Developmental milestones in type I spinal muscular atrophy","volume":"26","author":"De Sanctis","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.cmet.2018.03.004_bib35","doi-asserted-by":"crossref","unstructured":"De Vivo, D.C., Bertini, E., Hwu, W.-H., Foster, R., Bhan, I., Gheuens, S., Farwell, W., and Reyna, S.P. (2018). Nusinersen in infants who initiate treatment in a presymptomatic stage of SMA: interim efficacy and safety results from the phase 2 NURTURE Study. In MDA Clinical Conference (March 2014, Arlington, VA: The Muscular Dystrophy Association).","DOI":"10.1212\/WNL.92.15_supplement.S25.001"},{"key":"10.1016\/j.cmet.2018.03.004_bib36","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.S46.003","article-title":"Interim efficacy and safety results from the phase 2 NURTURE study evaluating nusinersen in presymptomatic infants with spinal muscular atrophy","volume":"88","author":"De Vivo","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.cmet.2018.03.004_bib37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ekir.2017.03.016","article-title":"Safety and tolerability study of an intravenously administered small interfering ribonucleic acid (siRNA) post on-pump cardiothoracic surgery in patients at risk of acute kidney injury","volume":"2","author":"Demirjian","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cmet.2018.03.004_bib38","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.2016.34.15_suppl.2547","article-title":"A phase I\/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC)","volume":"34","author":"Demuere","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cmet.2018.03.004_bib39","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2018.03.004_bib40","doi-asserted-by":"crossref","DOI":"10.2337\/dc17-2132","article-title":"Antisense inhibition of protein tyrosine phosphatase 1B With IONIS-PTP-1BRx improves insulin sensitivity and reduces weight in overweight patients with type 2 diabetes","author":"Digenio","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2018.03.004_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cmet.2018.03.004_bib42","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.cmet.2018.03.004_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/oli.1.2000.10.117","article-title":"Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?","volume":"10","author":"Eckstein","year":"2000","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.cmet.2018.03.004_bib44","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2018.03.004_bib45","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2018.03.004_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2018.03.004_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib49","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S0168-8278(17)30843-7","article-title":"A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population","volume":"66","author":"Gane","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2018.03.004_bib50","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib51","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib52","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jacl.2017.04.071","article-title":"The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS)","volume":"11","author":"Gaudet","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.cmet.2018.03.004_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.cmet.2018.03.004_bib54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3565(24)38831-7","article-title":"Pharmacokinetic properties of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib55","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"305","article-title":"Pharmacokinetic\/pharmacodynamic properties of phosphorothioate 2\u2032-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man","author":"Geary","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib56","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bcp.2009.04.013","article-title":"Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2\u2032-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN","volume":"78","author":"Geary","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cmet.2018.03.004_bib57","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cmet.2018.03.004_bib58","doi-asserted-by":"crossref","first-page":"A971","DOI":"10.1016\/S0735-1097(15)60971-8","article-title":"A phase 2, multi-center, open-label\u00a0trial to evaluate the safety, pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC, an RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis","volume":"65","author":"Gillmore","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cmet.2018.03.004_bib59","doi-asserted-by":"crossref","unstructured":"Gillmore, J.D., Falk, R.H., Maurer, M.S., Hanna, M., Fine, N., Powell, C., Karsten, V., Vest, J., Gollob, J., and Hawkins, P.N. (2016). Phase 2 open-label extension study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin amyloidosis with cardiomyopathy: Updated interim results. In International Symposium of Amyloidosis 2016 Abstract Book, p. PA84.","DOI":"10.1186\/1750-1172-10-S1-O21"},{"key":"10.1016\/j.cmet.2018.03.004_bib60","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the expanded hammersmith functional motor scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.cmet.2018.03.004_bib61","doi-asserted-by":"crossref","first-page":"e0161955","DOI":"10.1371\/journal.pone.0161955","article-title":"Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an open-label extension study","volume":"11","author":"Goemans","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2018.03.004_bib62","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cmet.2018.03.004_bib63","first-page":"564","article-title":"Phase 2 of bamosiran (SYL040012), a novel RNAi based compound for the treatment of increased intraocular pressure associated to glaucoma","volume":"55","author":"Gonzalez","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cmet.2018.03.004_bib64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib65","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"585","article-title":"The development of antisense oligonucleotides as antivirals","author":"Grillone","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib66","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.286.5441.950","article-title":"A species of small antisense RNA in posttranscriptional gene silencing in plants","volume":"286","author":"Hamilton","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.cmet.2018.03.004_bib67","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1093\/nar\/gkx507","article-title":"5\u2032-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in\u00a0vivo","volume":"45","author":"Haraszti","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib68","series-title":"Antisense Drug Technology: Principles,\u00a0Strategies, and Applications","first-page":"217","article-title":"Routes and formulations for delivery of antisense oligonucleotides","author":"Hardee","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib69","first-page":"409","article-title":"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase","volume":"12","author":"Henry","year":"1997","journal-title":"Anticancer Drug Des."},{"key":"10.1016\/j.cmet.2018.03.004_bib70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/019262339902700117","article-title":"Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1","volume":"27","author":"Henry","year":"1999","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.cmet.2018.03.004_bib71","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood.V126.23.2413.2413","article-title":"A subcutaneously administered investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: interim Phase 1 study results","volume":"126","author":"Hill","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cmet.2018.03.004_bib72","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood.V128.22.3891.3891","article-title":"A subcutaneously administered investigational RNAi Therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: preliminary phase 1\/2 study results in patients with PNH","volume":"128","author":"Hill","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmet.2018.03.004_bib73","doi-asserted-by":"crossref","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation\u00a0antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib74","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1517\/14740338.2013.793670","article-title":"Efficacy and safety of mipomersen sodium (Kynamro)","volume":"12","author":"Hovingh","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.cmet.2018.03.004_bib75","first-page":"1763","article-title":"A phase 1\/2 trial of ALN-GO1, an investigational RNAi therapeutic for primary hyperoxaluria type 1 (PH1)","volume":"31","author":"Hulton","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.cmet.2018.03.004_bib76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrm2321","article-title":"Argonaute proteins: key players in RNA silencing","volume":"9","author":"Hutvagner","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cmet.2018.03.004_bib77","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","article-title":"Cellular uptake and intracellular trafficking of oligonucleotides","volume":"87","author":"Juliano","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cmet.2018.03.004_bib79","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2016.16437","article-title":"Approving a problematic muscular dystrophy drug: implications for FDA policy","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cmet.2018.03.004_bib80","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib81","first-page":"909A","article-title":"Safety, pharmacokinetics, and biologic activity of ND-L02-s0201, a novel targeted lipid-nanoparticle to deliver HSP47 siRNA for the treatment of patients with advanced liver fibrosis: interim results from clinical phase 1b\/2 studies","volume":"62","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2018.03.004_bib82","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2009.273","article-title":"First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder","volume":"18","author":"Leachman","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2018.03.004_bib84","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"183","article-title":"Basic principles of the pharmacokinetics of antisense oligonucleotide drugs","author":"Levin","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib85","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bbagrm.2013.01.011","article-title":"Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells","volume":"1829","author":"Liang","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cmet.2018.03.004_bib86","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nbt.3589","article-title":"Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames","volume":"34","author":"Liang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cmet.2018.03.004_bib87","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib88","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.1093\/nar\/gkx632","article-title":"Antisense oligonucleotides targeting translation inhibitory elements in 5\u2032 UTRs can selectively increase protein levels","volume":"45","author":"Liang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib89","doi-asserted-by":"crossref","first-page":"AB273","DOI":"10.1016\/j.jaad.2015.02.1092","article-title":"Update on phase 2 clinical trial results of RXI-109 treatment to reduce the formation of hypertrophic dermal scars","volume":"72","author":"Libertine","year":"2015","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.cmet.2018.03.004_bib90","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"47","article-title":"The RNase H mechanism","author":"Lima","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib91","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2012.08.014","article-title":"Single-stranded siRNAs activate RNAi in animals","volume":"150","author":"Lima","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2018.03.004_bib92","doi-asserted-by":"crossref","first-page":"e101752","DOI":"10.1371\/journal.pone.0101752","article-title":"Defining the factors that contribute to on-target specificity of antisense oligonucleotides","volume":"9","author":"Lima","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2018.03.004_bib93","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/WNL.0000000000000926","article-title":"CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS","volume":"83","author":"Limmroth","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.cmet.2018.03.004_bib94","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","article-title":"Argonaute2 is the catalytic engine of mammalian RNAi","volume":"305","author":"Liu","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cmet.2018.03.004_bib95","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2018.03.004_bib96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2016.117","article-title":"Non-coding RNAs as drug targets","volume":"16","author":"Matsui","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cmet.2018.03.004_bib97","first-page":"1952","article-title":"Systemic pharmacodynamic efficacy of a complement factor B antisense oligonucleotide in preclinical and phase 1 clinical studies","volume":"58","author":"McCaleb","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cmet.2018.03.004_bib98","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrg3462","article-title":"Argonaute proteins: functional insights and emerging roles","volume":"14","author":"Meister","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.cmet.2018.03.004_bib99","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","article-title":"Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs","volume":"15","author":"Meister","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cmet.2018.03.004_bib100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.24843","article-title":"Reply","volume":"81","author":"Mendell","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cmet.2018.03.004_bib101","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cmet.2018.03.004_bib102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cmet.2018.03.004_bib103","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib104","doi-asserted-by":"crossref","first-page":"P3.166","DOI":"10.1212\/WNL.86.16_supplement.P3.166","article-title":"ISIS-DMPKRx in healthy volunteers: a placebo-controlled, randomized, single ascending-dose phase 1 Study","volume":"86","author":"Mignon","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.cmet.2018.03.004_bib105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cmet.2018.03.004_bib106","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2036.2004.01863.x","article-title":"An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis","volume":"19","author":"Miner","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib107","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib108","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/mt.2013.217","article-title":"Phase I clinical trial of SYL040012, a small interfering RNA targeting \u03b2-adrenergic receptor 2, for lowering intraocular pressure","volume":"22","author":"Moreno-Monta\u00f1\u00e9s","year":"2014","journal-title":"Mol. Ther."},{"issue":"Suppl1A","key":"10.1016\/j.cmet.2018.03.004_bib109","first-page":"LB28","article-title":"ISIS-GCGRRx, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy","volume":"63","author":"Morgan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2018.03.004_bib110","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.cmet.2018.03.004_bib111","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.cmet.2018.03.004_bib112","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib113","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1167\/iovs.12-9961","article-title":"Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study)","volume":"53","author":"Nguyen","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cmet.2018.03.004_bib114","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"O\u2019Hagen","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.cmet.2018.03.004_bib115","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1016\/S0040-4039(97)10322-7","article-title":"Synthesis of 2\u2032-O,4\u2032-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3\u2032-endo sugar puckering","volume":"38","author":"Obika","year":"1997","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.cmet.2018.03.004_bib116","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood.V128.22.1397.1397","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results from phase 1 and phase 2 extension studies in patients with inhibitors","volume":"128","author":"Pasi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmet.2018.03.004_bib117","first-page":"25","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: interim results from a phase 2 extension study in patients with Hemophilia A or B with and without inhibitors","volume":"1","author":"Pasi","year":"2017","journal-title":"RPTH"},{"key":"10.1016\/j.cmet.2018.03.004_bib118","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00007890-201407151-00467","article-title":"Treatment with QPI-1002, a short interfering (SI) RNA for the prophylaxis of delayed graft function","volume":"98","author":"Peddi","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.cmet.2018.03.004_bib119","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib120","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.bmcl.2016.04.063","article-title":"Synergistic effect of phosphorothioate, 5\u2032-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA","volume":"26","author":"Prakash","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cmet.2018.03.004_bib121","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","article-title":"Comprehensive structure-activity relationship of triantennary n-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes","volume":"59","author":"Prakash","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.cmet.2018.03.004_bib122","doi-asserted-by":"crossref","first-page":"6994","DOI":"10.1093\/nar\/gkx381","article-title":"Identification of metabolically stable 5\u2032-phosphate analogs that support single-stranded siRNA activity","volume":"45","author":"Prakash","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib123","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hon.2438_149","article-title":"Ph 1 trial evaluating MRG-106, a microrna-155 inhibitor, administered by intratumoral, subcutaneous, or intravenous delivery in cutaneous T-cell lymphoma (CTCL) patients","volume":"35","author":"Querfeld","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.cmet.2018.03.004_bib124","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of\u00a0LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2018.03.004_bib125","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2016.02.018","article-title":"Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia","volume":"10","author":"Raal","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.cmet.2018.03.004_bib126","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1182\/blood.V128.22.2572.2572","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results from a phase 1 and phase 1\/2 extension study in patients without inhibitors","volume":"128","author":"Ragni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmet.2018.03.004_bib127","series-title":"Methods for Treating or Preventing Transthyretin (TTR) Associated Diseases. WO\/2015\/042564","author":"Rajeev","year":"2015"},{"key":"10.1016\/j.cmet.2018.03.004_bib128","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2018.03.004_bib129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1089\/oli.2009.0180","article-title":"siRNA and innate immunity","volume":"19","author":"Robbins","year":"2009","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.cmet.2018.03.004_bib131","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1158\/1078-0432.CCR-11-0859","article-title":"Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c","volume":"17","author":"Saad","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib132","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cmet.2018.03.004_bib133","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cell.2015.06.029","article-title":"Single-molecule imaging reveals that argonaute reshapes the binding properties of its nucleic acid guides","volume":"162","author":"Salomon","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2018.03.004_bib134","doi-asserted-by":"crossref","first-page":"e14541","DOI":"10.1200\/JCO.2016.34.15_suppl.e14541","article-title":"Adoptive cellular immunotherapy with APN401, autologous Cbl-b-silenced peripheral blood mononuclear cells, in patients with solid tumors","volume":"34","author":"Salzberg","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cmet.2018.03.004_bib135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cmet.2018.03.004_bib136","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.P3.184","article-title":"Nusinersen in symptomatic children with later-onset Spinal Muscular Atrophy (SMA): design of the phase 3 CHERISH study","volume":"88","author":"Schneider","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.cmet.2018.03.004_bib137","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2013.55.0376","article-title":"First-in-human\u00a0phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors","volume":"32","author":"Schultheis","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cmet.2018.03.004_bib138","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1124\/jpet.102.036749","article-title":"Phase I trial of ISIS 104838, a 2\u2032-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha","volume":"303","author":"Sewell","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib139","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1038\/mtna.2016.31","article-title":"Elucidation of the biotransformation pathways of a Galnac3-conjugated antisense Oligonucleotide in rats and monkeys","volume":"5","author":"Shemesh","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.cmet.2018.03.004_bib140","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"75","article-title":"Small RNA silencing Pathways","author":"Sigova","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib141","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/nat.2014.0489","article-title":"Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection","volume":"24","author":"Solano","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib142","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2018.03.004_bib143","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/nar\/gkp841","article-title":"Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents","volume":"38","author":"Stein","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib144","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cmet.2018.03.004_bib145","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1016\/S0168-8278(17)31850-0","article-title":"A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg-Positive and -negative virally suppressed subjects with hepatitis B","volume":"66","author":"Sterinu-Cercel","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2018.03.004_bib146","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5414\/CPP50076","article-title":"Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors","volume":"50","author":"Strumberg","year":"2012","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib147","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.cmet.2018.03.004_bib148","unstructured":"Suhr, O.B., Coelho, T., Conceicao, I., Waddington Cruz, M., Schmidt, H., Buades, J., Campistol, J., Pouget, J., Berk, J., Polydefkis, M., et\u00a0al. (2016). Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR amyloidosis with polyneuropathy. In International Symposium of Amyloidosis 2016 Abstract Book, p. PA80."},{"key":"10.1016\/j.cmet.2018.03.004_bib149","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"143","article-title":"The medicinal chemistry of oligonucleotides","author":"Swayze","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib150","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib151","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jps.21084","article-title":"Oral delivery of antisense oligonucleotides in man","volume":"97","author":"Tillman","year":"2008","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.cmet.2018.03.004_bib152","first-page":"2530","article-title":"A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer","volume":"8","author":"Tolcher","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib153","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.atherosclerosis.2017.06.325","article-title":"Natural history and gene expression signature of platelet count in lipoprotein lipase deficiency","volume":"263","author":"Tremblay","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cmet.2018.03.004_bib154","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/2051-1426-3-S2-P175","article-title":"Phase I clinical trial of adoptive cellular immunotherapy with APN401 in patients with solid tumors","volume":"3","author":"Triozzi","year":"2015","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.cmet.2018.03.004_bib155","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2018.03.004_bib156","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S0168-8278(17)30447-6","article-title":"Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients","volume":"66","author":"Turner","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2018.03.004_bib157","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.24842","article-title":"Regarding \u201cEteplirsen for the treatment of Duchenne muscular dystrophy\u201d","volume":"81","author":"Unger","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cmet.2018.03.004_bib158","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2014.08.015","article-title":"Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients","volume":"111","author":"van der Ree","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib159","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.116.233809","article-title":"Renal effects of antisense-mediated inhibition of SGLT2","volume":"359","author":"van Meer","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib160","doi-asserted-by":"crossref","first-page":"e108625","DOI":"10.1371\/journal.pone.0108625","article-title":"Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms","volume":"9","author":"Vickers","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmet.2018.03.004_bib161","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1093\/nar\/gkv920","article-title":"The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA","volume":"43","author":"Vickers","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib162","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2018.03.004_bib163","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0002-9394(02)01327-2","article-title":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS","volume":"133","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.cmet.2018.03.004_bib164","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0002-9394(02)01326-0","article-title":"Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS","volume":"133","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.cmet.2018.03.004_bib165","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0002-9394(02)01332-6","article-title":"Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS","volume":"133","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.cmet.2018.03.004_bib166","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cmet.2018.03.004_bib167","first-page":"5577","article-title":"Main results of the First-In Human single ascending dose phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-\u03b22) in glaucoma filtration surgery","volume":"58","author":"Voykov","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cmet.2018.03.004_bib168","unstructured":"Wang, A.K., Coelho, T., Waddington Cruz, M., Polydefkis, M.J., Dyck, P.J., Scheinberg, M., Plante-Bordeneuve, V., Berk, J., Barroso, F., Adams, D., et\u00a0al. (2017a). Safety and Efficacy of Inotersen in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (NEURO-TTR). In 142nd Annual Meeting of the American Neurological Association (Oct 15-17, San Diego, CA), p. S318WIP."},{"key":"10.1016\/j.cmet.2018.03.004_bib169","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1093\/nar\/gkx231","article-title":"Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib170","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"117","article-title":"Basic principles of antisense drug discovery","author":"Watt","year":"2008"},{"key":"10.1016\/j.cmet.2018.03.004_bib171","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1021\/ar980051p","article-title":"Synthesis of 3\u2032-C- and 4\u2032-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA)","volume":"32","author":"Wengel","year":"1999","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.cmet.2018.03.004_bib172","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4161\/rna.28985","article-title":"Versatile microRNA biogenesis in animals and their viruses","volume":"11","author":"Xie","year":"2014","journal-title":"RNA Biol."},{"key":"10.1016\/j.cmet.2018.03.004_bib173","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.jconrel.2015.05.035","article-title":"Targeting glucose uptake of glioma cells by siRNA delivery with polymer nanoparticle","volume":"213","author":"Xu","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.cmet.2018.03.004_bib174","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.molcel.2015.05.015","article-title":"Single-molecule analysis of the target cleavage reaction by the Drosophila RNAi enzyme complex","volume":"59","author":"Yao","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cmet.2018.03.004_bib175","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","article-title":"Cross-species comparison of in\u00a0vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100","volume":"77","author":"Yu","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cmet.2018.03.004_bib176","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2018.03.004_bib177","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/17425255.2013.737320","article-title":"Clinical pharmacokinetics of second generation antisense oligonucleotides","volume":"9","author":"Yu","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.cmet.2018.03.004_bib178","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0168-8278(17)30316-1","article-title":"Prolonged RNA interference therapy with ARC-520 Injection in treatment na\u00efve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen","volume":"66","author":"Yuen","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2018.03.004_bib179","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.cardfail.2013.06.214","article-title":"Phase I first-in-humans trial of ALN-TTRsc, a novel RNA interference therapeutic for the treatment of familial amyloidotic cardiomyopathy (FAC)","volume":"19","author":"Zimmermann","year":"2013","journal-title":"J.\u00a0Card. Fail."},{"key":"10.1016\/j.cmet.2018.03.004_bib180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cmet.2018.03.004_bib181","first-page":"539","article-title":"Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions","volume":"6","author":"Zon","year":"1991","journal-title":"Anticancer Drug Des."},{"key":"10.1016\/j.cmet.2018.03.004_bib182","doi-asserted-by":"crossref","first-page":"20723","DOI":"10.1073\/pnas.1314307110","article-title":"Mutant KRAS is a druggable target for pancreatic cancer","volume":"110","author":"Zorde Khvalevsky","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cmet.2018.03.004_bib183","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"}],"updated-by":[{"DOI":"10.1016\/j.cmet.2019.01.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:00:00Z","timestamp":1549324800000}}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413118301827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413118301827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:29:15Z","timestamp":1761550155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413118301827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":183,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1550413118301827"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2018.03.004","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-Targeted Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}